First Trust Direct Indexing L.P. Cuts Position in Sanofi (NASDAQ:SNY)

First Trust Direct Indexing L.P. lessened its position in shares of Sanofi (NASDAQ:SNY) by 5.8% in the 1st quarter, HoldingsChannel reports. The fund owned 24,491 shares of the company’s stock after selling 1,512 shares during the period. First Trust Direct Indexing L.P.’s holdings in Sanofi were worth $1,190,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of SNY. Dynamic Advisor Solutions LLC purchased a new position in shares of Sanofi in the 4th quarter valued at about $2,104,000. Vestal Point Capital LP acquired a new position in shares of Sanofi in the 4th quarter valued at $14,919,000. Oxbow Advisors LLC purchased a new position in shares of Sanofi in the 4th quarter valued at $4,689,000. China Universal Asset Management Co. Ltd. lifted its position in Sanofi by 348.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 32,456 shares of the company’s stock valued at $1,614,000 after acquiring an additional 25,213 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new position in Sanofi in the fourth quarter valued at $4,704,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $48.86 on Friday. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.72. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm has a market cap of $123.75 billion, a price-to-earnings ratio of 24.55, a PEG ratio of 1.51 and a beta of 0.59. The stock’s 50-day moving average is $48.73 and its two-hundred day moving average is $48.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.96. The company had revenue of $11.36 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. Analysts predict that Sanofi will post 4.14 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.